Bal Pharma

{
  "main_header": {
    "sid": 555664,
    "name": "Bal Pharma",
    "stock_name": "Bal Pharma",
    "full_name": "Bal Pharma Ltd",
    "name_url": "stocks-analysis/bal-pharma",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "72.00",
    "chg": "0.00",
    "chgp": "0.00%",
    "dir": 0,
    "prev_price": "72.00",
    "mcapval": "115.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 524824,
    "symbol": "BALPHARMA",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE083D01012",
    "curr_date": "Mar 04",
    "curr_time": "",
    "bse_nse_vol": "5.01 k",
    "exc_status": "Active",
    "traded_date": "Mar 04, 2026",
    "traded_date_str": "2026 03 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/bal-pharma-555664-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Bal Pharma Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/bal-pharma-ltd-is-rated-strong-sell-3866193",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/BalPharmaLtd_mojoScore_3866193.png",
        "date": "2026-03-03 10:10:34",
        "description": "Bal Pharma Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 28 May 2025. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 03 March 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Bal Pharma Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/bal-pharma-ltd-is-rated-strong-sell-3848078",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/BalPharmaLtd_mojoScore_3848078.png",
        "date": "2026-02-20 10:10:49",
        "description": "Bal Pharma Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 28 May 2025. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 20 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Why is Bal Pharma Ltd falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-bal-pharma-ltd-fallingrising-3838721",
        "imagepath": "",
        "date": "2026-02-14 01:12:11",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Price Movement and Market Context</strong></p>\n<p>Bal Pharma Ltd has demonstrated a robust performance over the past week, gaining 8.70% while the Sensex declined by 1.14%. This divergence highlights the stock’s relative strength amid broader market weakness. Over the last month, the stock has appreciated by 6.37%, again contrasting with the Sensex’s 1.20% decline. Year-to-date, Bal Pharma has delivered a positive return of 3.21%, whereas the benchmark index has fallen by 3.04%. These figures indicate that the stock is currently benefiting from favourable investor sentiment and momentum, despite its longer-term underperformance.</p>\n<p>It is important to note that over a one-year horizon, Bal Pharma’s stock has declined by 25.19%, significantly lagging the Sensex’s 8.52% gain. Similar..."
      },
      {
        "title": "Are Bal Pharma Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-bal-pharma-ltd-latest-results-good-or-bad-3835689",
        "imagepath": "",
        "date": "2026-02-12 19:44:56",
        "description": "Bal Pharma Ltd's latest financial results for the quarter ended December 2025 reveal a complex picture of performance. The company reported net sales of ₹87.69 crores, marking a year-on-year growth of 19.88%, a notable recovery from a previous decline. This revenue growth is the highest quarterly figure recorded by the company, indicating potential improvements in demand or market positioning.\n\nHowever, despite this top-line growth, the operational efficiency remains a concern. The operating margin, which stands at 10.89%, has only marginally improved from the previous year, suggesting persistent cost pressures and pricing challenges that are impacting profitability. The profit after tax (PAT) of ₹1.78 crores reflects a dramatic year-on-year increase of 270.83%, but this figure is modest in absolute terms relative to the company's revenue.\n\nThe financial metrics also highlight ongoing challenges with capita..."
      },
      {
        "title": "Bal Pharma Q3 FY26: Strong Quarter Masks Deeper Structural Concerns",
        "link": "https://www.marketsmojo.com/news/result-analysis/bal-pharma-q3-fy26-strong-quarter-masks-deeper-structural-concerns-3835138",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/BalPharma_quaterlyResult_3835138.png",
        "date": "2026-02-12 09:41:23",
        "description": "Bal Pharma Ltd., a Bangalore-based pharmaceutical manufacturer and member of the Micro Laboratories Group, reported consolidated net profit of ₹1.78 crores for Q3 FY26 (October-December 2025), marking a dramatic 270.83% year-on-year surge from ₹0.48 crores in Q3 FY25. The micro-cap pharmaceutical company, with a market capitalisation of ₹121.00 crores, saw its stock surge 6.79% to ₹75.82 following the results announcement, though the shares remain 41.16% below their 52-week high of ₹128.86."
      },
      {
        "title": "Are Bal Pharma Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-bal-pharma-ltd-latest-results-good-or-bad-3833422",
        "imagepath": "",
        "date": "2026-02-11 19:34:15",
        "description": "Bal Pharma Ltd's latest financial results for the quarter ending September 2025 highlight several operational challenges. The company reported net sales of ₹74.02 crores, reflecting a marginal year-on-year growth of 0.45% from ₹73.69 crores in the same quarter last year. However, this growth is significantly subdued compared to the broader industry trends. \n\nNet profit for the quarter was ₹0.71 crores, which represents a decline of 31.73% year-on-year, contrasting with a profit of ₹1.04 crores in the previous year. This decline in profitability is concerning, especially as it comes amidst a backdrop of rising operational costs and pressures on margins. The operating margin for Bal Pharma fell to 7.73%, marking the lowest level in eight quarters, down from 10.44% a year ago. This compression in margins indicates fundamental challenges in cost management and pricing power, as the company struggles to pass on ..."
      },
      {
        "title": "Bal Pharma Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/bal-pharma-ltd-is-rated-strong-sell-3828535",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/BalPharmaLtd_mojoScore_3828535.png",
        "date": "2026-02-09 10:10:30",
        "description": "Bal Pharma Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 28 May 2025, reflecting a significant reassessment of the stock’s outlook. However, the analysis and financial metrics discussed below represent the company’s current position as of 09 February 2026, providing investors with an up-to-date view of its performance and prospects."
      },
      {
        "title": "When is the next results date for Bal Pharma Ltd?",
        "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-bal-pharma-ltd-3821214",
        "imagepath": "",
        "date": "2026-02-04 23:17:00",
        "description": "The next results date for Bal Pharma Ltd is scheduled for 11 February 2026...."
      },
      {
        "title": "Bal Pharma Ltd Stock Hits 52-Week Low Amidst Continued Downtrend",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bal-pharma-ltd-stock-hits-52-week-low-amidst-continued-downtrend-3816450",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/BalPharmaLtd_priceRelatedfactors_3816450.png",
        "date": "2026-02-02 11:19:53",
        "description": "Bal Pharma Ltd’s shares declined sharply to a fresh 52-week low of Rs.64 on 2 Feb 2026, marking a significant downturn in the stock’s performance over the past year. The stock’s fall reflects ongoing pressures on the company’s financial metrics and relative underperformance within the Pharmaceuticals & Biotechnology sector."
      }
    ],
    "total": 127,
    "sid": "555664",
    "stock_news_url": "https://www.marketsmojo.com/news/bal-pharma-555664"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "16-Feb-2026",
      "details": "Newspaper publication of Unaudited financial results for the quarter ended 31.12.2025.",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Outcome for Outcome Of The Board Meeting_ Standalone And Consolidated Financial Results For The Quarter Ended 31.12.2025.",
      "datetime": "11-Feb-2026",
      "details": "Unaudited standalone and consolidated financial results for the quarter ended 31.12.2025.",
      "source": "BSE"
    },
    {
      "caption": "Financial Results_31.12.2025",
      "datetime": "11-Feb-2026",
      "details": "Unaudited standalone and consolidated financial results for the quarter ended 31.12.2025.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Bal Pharma Ltd has declared <strong>12%</strong> dividend, ex-date: 18 Sep 25",
          "dt": "2025-09-18",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Bal Pharma Ltd is Rated Strong Sell

2026-03-03 10:10:34

Bal Pharma Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 28 May 2025. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 03 March 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Bal Pharma Ltd is Rated Strong Sell

2026-02-20 10:10:49

Bal Pharma Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 28 May 2025. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 20 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Why is Bal Pharma Ltd falling/rising?

2026-02-14 01:12:11

Recent Price Movement and Market Context

Bal Pharma Ltd has demonstrated a robust performance over the past week, gaining 8.70% while the Sensex declined by 1.14%. This divergence highlights the stock’s relative strength amid broader market weakness. Over the last month, the stock has appreciated by 6.37%, again contrasting with the Sensex’s 1.20% decline. Year-to-date, Bal Pharma has delivered a positive return of 3.21%, whereas the benchmark index has fallen by 3.04%. These figures indicate that the stock is currently benefiting from favourable investor sentiment and momentum, despite its longer-term underperformance.

It is important to note that over a one-year horizon, Bal Pharma’s stock has declined by 25.19%, significantly lagging the Sensex’s 8.52% gain. Similar...

Read full news article

Are Bal Pharma Ltd latest results good or bad?

2026-02-12 19:44:56

Bal Pharma Ltd's latest financial results for the quarter ended December 2025 reveal a complex picture of performance. The company reported net sales of ₹87.69 crores, marking a year-on-year growth of 19.88%, a notable recovery from a previous decline. This revenue growth is the highest quarterly figure recorded by the company, indicating potential improvements in demand or market positioning. However, despite this top-line growth, the operational efficiency remains a concern. The operating margin, which stands at 10.89%, has only marginally improved from the previous year, suggesting persistent cost pressures and pricing challenges that are impacting profitability. The profit after tax (PAT) of ₹1.78 crores reflects a dramatic year-on-year increase of 270.83%, but this figure is modest in absolute terms relative to the company's revenue. The financial metrics also highlight ongoing challenges with capita...

Read full news article

Bal Pharma Q3 FY26: Strong Quarter Masks Deeper Structural Concerns

2026-02-12 09:41:23

Bal Pharma Ltd., a Bangalore-based pharmaceutical manufacturer and member of the Micro Laboratories Group, reported consolidated net profit of ₹1.78 crores for Q3 FY26 (October-December 2025), marking a dramatic 270.83% year-on-year surge from ₹0.48 crores in Q3 FY25. The micro-cap pharmaceutical company, with a market capitalisation of ₹121.00 crores, saw its stock surge 6.79% to ₹75.82 following the results announcement, though the shares remain 41.16% below their 52-week high of ₹128.86.

Read full news article

Are Bal Pharma Ltd latest results good or bad?

2026-02-11 19:34:15

Bal Pharma Ltd's latest financial results for the quarter ending September 2025 highlight several operational challenges. The company reported net sales of ₹74.02 crores, reflecting a marginal year-on-year growth of 0.45% from ₹73.69 crores in the same quarter last year. However, this growth is significantly subdued compared to the broader industry trends. Net profit for the quarter was ₹0.71 crores, which represents a decline of 31.73% year-on-year, contrasting with a profit of ₹1.04 crores in the previous year. This decline in profitability is concerning, especially as it comes amidst a backdrop of rising operational costs and pressures on margins. The operating margin for Bal Pharma fell to 7.73%, marking the lowest level in eight quarters, down from 10.44% a year ago. This compression in margins indicates fundamental challenges in cost management and pricing power, as the company struggles to pass on ...

Read full news article

Bal Pharma Ltd is Rated Strong Sell

2026-02-09 10:10:30

Bal Pharma Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 28 May 2025, reflecting a significant reassessment of the stock’s outlook. However, the analysis and financial metrics discussed below represent the company’s current position as of 09 February 2026, providing investors with an up-to-date view of its performance and prospects.

Read full news article

When is the next results date for Bal Pharma Ltd?

2026-02-04 23:17:00

The next results date for Bal Pharma Ltd is scheduled for 11 February 2026....

Read full news article

Bal Pharma Ltd Stock Hits 52-Week Low Amidst Continued Downtrend

2026-02-02 11:19:53

Bal Pharma Ltd’s shares declined sharply to a fresh 52-week low of Rs.64 on 2 Feb 2026, marking a significant downturn in the stock’s performance over the past year. The stock’s fall reflects ongoing pressures on the company’s financial metrics and relative underperformance within the Pharmaceuticals & Biotechnology sector.

Read full news article

View All News